{
    "root": "95dafbc7-2a78-4e20-9cf2-abfb70a0f108",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tocilizumab-anoh",
    "value": "20250131",
    "ingredients": [
        {
            "name": "tocilizumab",
            "code": "I031V2H011"
        }
    ],
    "indications": "tocilizumab-anoh interleukin-6 ( il-6 ) receptor antagonist indicated treatment : rheumatoid arthritis ( rheumatoid arthritis ) ( 1.1 ) adult patients moderately severely active rheumatoid arthritis inadequate response one disease-modifying anti-rheumatic drugs ( dmards ) . giant cell arteritis ( gca ) ( 1.2 ) adult patients giant cell arteritis . polyarticular juvenile idiopathic arthritis ( pjia ) ( 1.3 ) patients 2 years age older active polyarticular juvenile idiopathic arthritis . systemic juvenile idiopathic arthritis ( sjia ) ( 1.4 ) patients 2 years age older active systemic juvenile idiopathic arthritis . coronavirus disease 2019 ( covid-19 ) ( 1.5 ) hospitalized adult patients coronavirus disease 2019 ( covid-19 ) receiving systemic corticosteroids require supplemental oxygen , non-invasive invasive mechanical ventilation , extracorporeal membrane oxygenation ( ecmo ) .",
    "contraindications": "rheumatoid arthritis , pjia sjia , tocilizumab-anoh may used alone combination methotrexate : rheumatoid arthritis , non-biologic dmards may used . ( 2 ) general dosing information ( 2.1 ) rheumatoid arthritis , gca , pjia sjia \u2013 recommended tocilizumab-anoh initiated patients absolute neutrophil count ( anc ) 2000 per mm 3 , platelet count 100,000 per mm 3 , alt ast 1.5 times upper limit normal ( uln ) ( 5.3 , 5.4 ) . covid-19 \u2013 recommended tocilizumab-anoh initiated patients absolute neutrophil count ( anc ) 1000 per mm 3 , platelet count 50,000 mm 3 , alt ast 10 times uln ( 5.3 , 5.4 ) . rheumatoid arthritis covid-19 patients , tocilizumab-anoh doses exceeding 800 mg per infusion recommended . ( 2.2 , 2.6 , 12.3 ) gca patients , tocilizumab-anoh doses exceeding 600 mg per infusion recommended . ( 2.3 , 12.3 ) rheumatoid arthritis ( 2.2 ) recommended adult intravenous : used combination non-biologic dmards monotherapy recommended starting dose 4 mg per kg every 4 weeks followed increase 8 mg per kg every 4 weeks based response . recommended adult subcutaneous : patients less 100 kg weight 162 mg administered subcutaneously every week , followed increase every week based response patients 100 kg weight 162 mg administered subcutaneously every week giant cell arteritis ( 2.3 ) recommended adult intravenous : recommended dose 6 mg per kg every 4 weeks combination tapering course glucocorticoids . tocilizumab-anoh used alone following discontinuation glucocorticoids . recommended adult subcutaneous : recommended dose 162 mg given every week subcutaneous injection , combination tapering course glucocorticoids . dose 162 mg given every week subcutaneous injection , combination tapering course glucocorticoids , may prescribed based considerations . tocilizumab-anoh used alone following discontinuation glucocorticoids . polyarticular juvenile idiopathic arthritis ( 2.4 ) recommended intravenous pjia every 4 weeks patients less 30 kg weight 10 mg per kg patients 30 kg weight 8 mg per kg recommended subcutaneous pjia patients less 30 kg weight 162 mg every three weeks patients 30 kg weight 162 mg every two weeks systemic juvenile idiopathic arthritis ( 2.5 ) recommended intravenous sjia every 2 weeks patients less 30 kg weight 12 mg per kg patients 30 kg weight 8 mg per kg recommended subcutaneous sjia patients less 30 kg weight 162 mg every two weeks patients 30 kg weight 162 mg every week coronavirus disease 2019 ( 2.6 ) recommended tocilizumab-anoh adult patients covid-19 8 mg per kg administered 60-minute intravenous infusion . intravenous formulation ( 2.7 ) patients rheumatoid arthritis , gca , covid-19 , pjia , sjia patients 30 kg , dilute 100 ml 0.9 % 0.45 % sodium chloride injection , usp intravenous infusion using aseptic technique . pjia sjia patients less 30 kg , dilute 50 ml 0.9 % 0.45 % sodium chloride injection , usp intravenous infusion using aseptic technique . administer single intravenous drip infusion 1 hour ; administer bolus push . subcutaneous formulation ( 2.8 ) follow instructions prefilled syringe prefilled autoinjector dose modifications ( 2.9 ) recommended management certain dose-related laboratory changes including elevated liver enzymes , neutropenia , thrombocytopenia .",
    "warningsAndPrecautions": null,
    "adverseReactions": "tocilizumab-anoh contraindicated patients known hypersensitivity tocilizumab products [ ( 5.6 ) ] .",
    "indications_original": "Tocilizumab-anoh is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Coronavirus Disease 2019 (COVID-19) ( 1.5 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).",
    "contraindications_original": "For RA, pJIA and sJIA, Tocilizumab-anoh may be used alone or in combination with methotrexate: and in RA, other non-biologic DMARDs may be used. ( 2 ) General Administration and Dosing Information ( 2.1 ) RA, GCA, PJIA and SJIA \u2013 It is recommended that Tocilizumab-anoh not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm 3 , platelet count below 100,000 per mm 3 , or ALT or AST above 1.5 times the upper limit of normal (ULN) ( 5.3 , 5.4 ) . COVID-19 \u2013 It is recommended that Tocilizumab-anoh not be initiated in patients with an absolute neutrophil count (ANC) below 1000 per mm 3 , platelet count below 50,000 mm 3 , or ALT or AST above 10 times ULN ( 5.3 , 5.4 ) . In RA or COVID-19 patients, Tocilizumab-anoh doses exceeding 800 mg per infusion are not recommended. ( 2.2 , 2.6 , 12.3 ) In GCA patients, Tocilizumab-anoh doses exceeding 600 mg per infusion are not recommended. ( 2.3 , 12.3 ) Rheumatoid Arthritis ( 2.2 ) Recommended Adult Intravenous Dosage: When used in combination with non-biologic DMARDs or as monotherapy the recommended starting dose is 4 mg per kg every 4 weeks followed by an increase to 8 mg per kg every 4 weeks based on clinical response. Recommended Adult Subcutaneous Dosage: Patients less than 100 kg weight 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response Patients at or above 100 kg weight 162 mg administered subcutaneously every week Giant Cell Arteritis ( 2.3 ) Recommended Adult Intravenous Dosage: The recommended dose is 6 mg per kg every 4 weeks in combination with a tapering course of glucocorticoids. Tocilizumab-anoh can be used alone following discontinuation of glucocorticoids. Recommended Adult Subcutaneous Dosage: The recommended dose is 162 mg given once every week as a subcutaneous injection, in combination with a tapering course of glucocorticoids. A dose of 162 mg given once every other week as a subcutaneous injection, in combination with a tapering course of glucocorticoids, may be prescribed based on clinical considerations. Tocilizumab-anoh can be used alone following discontinuation of glucocorticoids. Polyarticular Juvenile Idiopathic Arthritis ( 2.4 ) Recommended Intravenous PJIA Dosage Every 4 Weeks Patients less than 30 kg weight 10 mg per kg Patients at or above 30 kg weight 8 mg per kg Recommended Subcutaneous PJIA Dosage Patients less than 30 kg weight 162 mg once every three weeks Patients at or above 30 kg weight 162 mg once every two weeks Systemic Juvenile Idiopathic Arthritis ( 2.5 ) Recommended Intravenous SJIA Dosage Every 2 Weeks Patients less than 30 kg weight 12 mg per kg Patients at or above 30 kg weight 8 mg per kg Recommended Subcutaneous SJIA Dosage Patients less than 30 kg weight 162 mg every two weeks Patients at or above 30 kg weight 162 mg every week Coronavirus Disease 2019 ( 2.6 ) The recommended dosage of Tocilizumab-anoh for adult patients with COVID-19 is 8 mg per kg administered by a 60-minute intravenous infusion. Administration of Intravenous Formulation ( 2.7 ) For patients with RA, GCA, COVID-19, PJIA, and SJIA patients at or above 30 kg, dilute to 100 mL in 0.9% or 0.45% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique. For PJIA and SJIA patients less than 30 kg, dilute to 50 mL in 0.9% or 0.45% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique. Administer as a single intravenous drip infusion over 1 hour; do not administer as bolus or push. Administration of Subcutaneous Formulation ( 2.8 ) Follow the Instructions for Use for prefilled syringe and prefilled autoinjector Dose Modifications ( 2.9 ) Recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia.",
    "adverseReactions_original": "Tocilizumab-anoh is contraindicated in patients with known hypersensitivity to tocilizumab products [see Warnings and Precautions (5.6)]."
}